Vincent Aranzana-Climent Selected Research

apramycin

10/2022	Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia.
9/2021	Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vincent Aranzana-Climent Research Topics

Disease

5	Infections 01/2023 - 12/2017
1	Pneumonia (Pneumonitis) 10/2022
1	Meningitis 09/2022
1	Central Nervous System Infections (Central Nervous System Infection) 09/2022
1	Bacterial Pneumonia 01/2022

Drug/Important Bio-Agent (IBA)

2	Carbapenems (Carbapenem Antibiotics)IBA 10/2022 - 09/2021
2	apramycinIBA 10/2022 - 09/2021
2	Anti-Bacterial Agents (Antibiotics)IBA 09/2022 - 01/2022
1	Polymyxin B (Aerosporin)FDA LinkGeneric 01/2023
1	Anti-Infective Agents (Microbicides)IBA 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	IronIBA 01/2022
1	LactamsIBA 01/2022
1	Colistin (Coly-Mycin)FDA Link 12/2017

Therapy/Procedure

1	Phage Therapy 01/2022
1	Therapeutics 09/2021